FDA Rejects Ivonescimab: Overall Survival Missed Significance at p=0.057, a Gap of 0.007
The FDA issued a complete response letter for Summit's ivonescimab on November 15. HARMONi's overall survival hazard ratio was 0.79 (95% CI 0.62 to 1.01, p=0.057), and the FDA had said in advance that a significant survival benefit was needed.

On November 15, a day after its FDA action date, Summit Therapeutics announced that the agency had issued a complete response letter for ivonescimab, its PD-1 and VEGF bispecific antibody, in EGFR-mutated non-small cell lung cancer after treatment with a targeted therapy. The application rested on a phase 3 trial called HARMONi.
The reason is in one number. Overall survival, the trial's second primary endpoint, had a hazard ratio of 0.79 and a p-value of 0.057. The conventional threshold is 0.05. The gap is 0.007, and the FDA had said it mattered.
What did HARMONi show?
HARMONi randomized 420 patients (ClinicalTrials.gov, NCT06396065) to ivonescimab plus platinum chemotherapy or placebo plus chemotherapy. It had two primary endpoints, progression-free survival and overall survival. Summit reports the results in its quarterly filing with the SEC.
Every hazard ratio favoured ivonescimab, but the one the FDA required, overall survival at 0.79, had a p-value of 0.057 and a confidence interval reaching 1.01.
Hazard ratios, ivonescimab plus chemotherapy versus chemotherapy. Below 1.0 favours ivonescimab. PFS is progression-free survival, OS is overall survival.
Source: Summit Therapeutics, Form 10-Q for the quarter ended September 30, 2026. PFS primary 0.52 (95% CI 0.41 to 0.66, p<0.00001); PFS longer follow-up 0.57 (0.46 to 0.71); OS primary 0.79 (0.62 to 1.01, p=0.057); OS ad hoc September 2025 analysis 0.78 (0.62 to 0.98, nominal p=0.0332); OS in Western patients 0.84 (medians 17.0 vs 14.0 months); OS in the single-region HARMONi-A study 0.74, reported as significant. The ad hoc and subgroup analyses were not the prespecified primary test.
View data
| analysis | hr |
|---|---|
| PFS, primary | 0.52 |
| PFS, longer follow-up | 0.57 |
| OS, primary analysis | 0.79 |
| OS, ad hoc (Western) | 0.78 |
| OS, Western patients | 0.84 |
| OS, HARMONi-A | 0.74 |
Progression-free survival was strong: a hazard ratio of 0.52 (95% CI 0.41 to 0.66), with median PFS of 6.8 months against 4.4 months. Overall survival was positive in direction but not in significance: 0.79, with a confidence interval of 0.62 to 1.01 that just touches 1. A later ad hoc analysis that followed Western patients for longer gave a hazard ratio of 0.78 and a nominal p-value of 0.0332, but nominal means it was not part of the prespecified test and was not corrected for looking again.
Did the FDA warn Summit?
Yes, in writing, and Summit disclosed it. The company's 10-Q says the FDA accepted the application in January 2026 with an action date of November 14, 2026, and that the agency noted a statistically significant overall survival benefit is necessary for approval in this setting and that the progression-free survival results alone may not be enough. Summit filed anyway, citing the consistent direction of the survival data and the lack of approved regimens with a proven survival benefit in this setting.
That is a bet that the agency would accept a strong progression-free survival result and a trend in survival. The complete response letter indicates it would not: press coverage of Summit's announcement says the survival result lacked statistical significance. We could not open the letter or the press release itself; the account of the decision here rests on Summit's SEC filing before the decision and on press reports of the announcement.
What happens to the program and the company?
The next test is HARMONi-3, a first-line lung cancer trial. ClinicalTrials.gov lists it as active, not recruiting, with a planned 1,600 patients and an estimated primary completion date of December 31, 2028. A letter for the second-line application does not directly change that trial, but if the first-line trial becomes the route to a United States approval, its estimated completion points to 2028 or later.
The balance sheet looks different from the usual rejected-biotech story. At September 30, Summit held $150.8 million in cash and $479.0 million in short-term investments, together $629.8 million, against a nine-month net loss of $613.5 million. After the quarter it received $2.0 billion in gross proceeds from AstraZeneca in connection with an equity investment. Adding that to the September 30 balances gives about $2.6 billion, before any spending since. At the nine-month loss rate, that is roughly three years of runway, our arithmetic rather than a company statement.
What this does and does not show
The numbers show how narrow the statistical miss was, and that the FDA had told the company its bar. They do not show whether ivonescimab extends survival, and a p-value of 0.057 is not evidence that it does not. They also do not show why the FDA drew this line, since the letter is not public. Summit's account of the precedent for approvals without a significant survival benefit is a company argument we did not verify. The ad hoc analyses were chosen after the primary result was known, so they cannot settle the question. All HARMONi figures are Summit-reported; we did not see the full trial report.
Sources
- Summit Therapeutics, Form 10-Q for the quarter ended September 30, 2026, filed November 4, 2026: HARMONi hazard ratios and p-values, the FDA statement on overall survival, the November 14 action date, cash, short-term investments, net loss and the $2.0 billion AstraZeneca proceeds.
- Summit Therapeutics, Provides Update Regarding Ivonescimab Biologics License Application, November 15, 2026 (Business Wire): the complete response letter. We could not open this page and cite it from search results; a GuruFocus summary of the same announcement says the survival result was not statistically significant.
- ClinicalTrials.gov, HARMONi, NCT06396065 (420 patients enrolled) and HARMONi-3, NCT05899608 (1,600 planned; primary completion estimated December 31, 2028).
- Related on this site: FDA has approved 46 novel drugs by October 9.
Recommended Reading

The First Huntington’s Gene Therapy Filing Rests on 12 Patients. Its Effect Ranges From 44% to 75% Depending on the Comparison

HHS Opened Six Peptides to Compounding. The Trial Register Lists Five Trials of Them, None Finished

Half of FDA's New Drugs Already Target Rare Diseases. The New Framework Aims at the Other 95%
Discussion (0)
Sign in to join the conversation and share your thoughts
No comments yet. Be the first to start the discussion!